NDA 218730 · Vertex Pharms INC
Alyftrek
Deutivacaftor, Tezacaftor, Vanzacaftor Calcium · Oral · Cystic Fibrosis Transmembrane Conductance Regulator Potentiator
NovelPriority reviewOrphanCDER novel approval, Dec 20, 2024: For the treatment of cystic fibrosis (CF) in patients 6 years of age and older
Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Dec 20, 2024
Approved uses
2
Original approval plus efficacy supplements
Registered trials
16
5 Phase 3, 3 recruiting
FAERS reports
789
375 serious, 7 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: DRUG-INDUCED LIVER INJURY AND LIVER FAILURE Elevated transaminases have been observed in patients treated with ALYFTREK. Cases of serious and potentially fatal drug-induced liver injury and liver failure were reported in patients who were taking a fixed-dose combination drug containing elexacaftor, tezacaftor, and ivacaftor, which contains the same or similar active ingredients as ALYFTREK. Liver injury has been reported within the first month of therapy and up to 15 months following initiation of elexacaftor/tezacaftor/ivacaftor [see Warnings and Precautions (5.1) and Adverse Reactions (6) ]. Assess liver function tests (ALT, AST, alkaline phosphatase, and bilirubin) in all patients prior to initiating ALYFTREK, every month during the first 6 months of treatment, then every 3 months for the next 12 months, then at least annually thereafter. Consider more frequent monitoring...
What it is approved for
From the label in effect Aug 26, 2026.
ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in adult and pediatric patients 6 years of age and older who have a clinical diagnosis of CF and who have at least one variant in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is either responsive based on clinical and/or in vitro data (see Table 5 ) or results in production of CFTR protein [see Clinical Pharmacology (12.1) ]. If the patient's genotype is unknown, an FDA-cleared CF genetic test should be used to confirm the presence of at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. ALYFTREK is a combination of deutivacaftor, a CFTR potentiator, tezacaftor, and vanzacaftor indicated for the treatment of cystic fibrosis (CF) in adult and pediatric patients aged 6 years and older who have a clinical diagnosis of CF and who have at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. ( 1 , 12.1 ) If the patient's genotype is unknown, an FDA-cleared CF genetic test should be used to confirm the presence of at least one variant in the CFTR gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. ( 1 )
Mechanism: Vanzacaftor and tezacaftor bind to different sites on the CFTR protein and have an additive effect in facilitating the cellular processing and trafficking of select mutant forms of CFTR (including F508del- CFTR) to increase the amount of CFTR protein delivered to the cell surface compared to either molecule alone. Deutivacaftor potentiates the channel open probability (or gating) of the CFTR protein at the cell surface. The combined effect of vanzacaftor, tezacaftor and deutivacaftor is increased quantity and function of CFTR at the cell surface, resulting in increased CFTR activity as...
Therapeutic areas: Respiratory
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 27, 2026 Supplement 1 · Efficacy · priority review OrphanLabelMedication GuideLetter
- Dec 20, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
2 products under this application
- ALYFTREK · DEUTIVACAFTOR 125MG; TEZACAFTOR 50MG; VANZACAFTOR CALCIUM EQ 10MG BASE · TABLET, ORAL · Prescription
- ALYFTREK · DEUTIVACAFTOR 50MG; TEZACAFTOR 20MG; VANZACAFTOR CALCIUM EQ 4MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Deutivacaftor" as an intervention, any sponsor and status, largest first.
- A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination TherapyPivotal-lookingActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05444257 · 822 participants · Start Nov 8, 2022 · Primary completion Oct 30, 2026
Drug: VX-121/TEZ/D-IVA · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 195 sites in all
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05076149 · 597 participants · Start Oct 27, 2021 · Primary completion May 18, 2023
Drug: VX-121/TEZ/D-IVA; ELX/TEZ/IVA and 4 more · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 170 sites in all
- A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)Pivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05033080 · 435 participants · Start Sep 14, 2021 · Primary completion May 12, 2023
Drug: VX-121/TEZ/D-IVA; ELX/TEZ/IVA and 4 more · For: Cystic Fibrosis
Sites: Birmingham, Alabama; Tucson, Arizona; Little Rock, Arkansas · 139 sites in all
- Evaluation of VX-121/Tezacaftor/Deutivacaftor in Cystic Fibrosis (CF) Participants 1 Through 11 Years of AgePivotal-lookingActive, not recruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05422222 · 210 participants (planned) · Start Jun 21, 2022 · Primary completion Jun 30, 2030
Drug: VX-121/TEZ/D-IVA · For: Cystic Fibrosis
Sites: Orange, California; Palo Alto, California; Aurora, Colorado · 38 sites in all
- Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and OlderPivotal-lookingEnrolling by invitation
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT05844449 · 174 participants (planned) · Start Aug 11, 2023 · Primary completion Jul 30, 2029
Drug: VNZ/TEZ/D-IVA · For: Cystic Fibrosis
Sites: Orange, California; Palo Alto, California; Aurora, Colorado · 37 sites in all
- Evaluation of VX-828 in Healthy Participants and in Participants With Cystic FibrosisPivotal-lookingCompleted
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06154447 · 165 participants · Start Dec 12, 2023 · Primary completion Jul 10, 2026
Drug: VX-828; Placebo and 7 more · For: Cystic Fibrosis
Sites: Hollywood, Florida; Orlando, Florida; Overland Park, Kansas · 12 sites in all
- Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07437105 · 160 participants (planned) · Start Feb 25, 2026 · Primary completion Jun 26, 2027
Drug: VX-272; Placebo and 2 more · For: Cystic Fibrosis
Sites: Tempe, Arizona
- Evaluation of VX-581 in Healthy Participants and in Participants With Cystic FibrosisPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT07283770 · 152 participants (planned) · Start Dec 9, 2025 · Primary completion Jul 12, 2027
Drug: VX-581; Placebo and 5 more · For: Cystic Fibrosis
Sites: Overland Park, Kansas
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hospitalisation68
- headache53
- anxiety48
- rash47
- fatigue45
- dyspnoea39
- infective pulmonary exacerbation of cystic fibrosis34
- diarrhoea33
- liver function test increased33
- nausea33
- haemoptysis24
- alanine aminotransferase increased23
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2024 | 2 |
| 2025 | 344 |
| 2026 | 443 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Vanzacaftor-tezacaftor-deutivacaftor versus elexacaftor-tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials.
Keating C, Yonker LM, Vermeulen F, et al. · Lancet Respir Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials.
Uluer AZ, MacGregor G, Azevedo P, et al. · Lancet Respir Med 2023 · Randomized Controlled Trial, Clinical Trial, Phase II
- Vanzacaftor-tezacaftor-deutivacaftor for children aged 6-11 years with cystic fibrosis (RIDGELINE Trial VX21-121-105): an analysis from a single-arm, phase 3 trial.
Hoppe JE, Kasi AS, Pittman JE, et al. · Lancet Respir Med 2025 · Multicenter Study, Clinical Trial, Phase III
- Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del).
Heneghan M, Southern KW, Murphy J, et al. · Cochrane Database Syst Rev 2023 · Research Support, Non-U.S. Gov't, Systematic Review
- Improvements in health-related quality of life in people with cystic fibrosis ࣙ6 years of age treated with vanzacaftor/tezacaftor/deutivacaftor.
Wainwright CE, Thorat T, Conner S, et al. · J Cyst Fibros 2026 · Clinical Trial, Phase III
- Comparative Efficacy of CFTR Modulators: A Network Meta-analysis.
Iftikhar IH, Rao ST, Nadama R, et al. · Lung 2025 · Comparative Study, Network Meta-Analysis
Sponsor: Vertex Pharmaceuticals
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.